New hope for ovarian cancer patients with residual disease after surgery
NCT ID NCT02884648
Summary
This study is testing whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that was discovered during a second surgery after initial treatment. The research involves 35 participants who have completed standard chemotherapy and surgery but still have cancer cells present. Participants receive bevacizumab by IV every 3 weeks for as long as it continues to help them, with regular scans to monitor progress.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.